717 A phase 1/2 study of AU-007, a monoclonal antibody (mAb) that binds to IL-2 and inhibits CD25 binding, in patients with advanced solid tumors: interim results from dose escalation

• Andrew Haydon,
• John Powderly,
• Timothy Wyant,
• James Vasselli,
• Drew Rasco,
• Meredith McKean,
• Elizabeth Ahern,
• Sophia Frentzas,
• Andrew Weickhardt,
• Inbar Amit,
• Aron Knickerbocker,
• Yanay Ofran,
• Paul de Souza,
• Jenny Tang,
• Lori Richards

Affiliations

Andrew Haydon

Medical Oncology, The Alfred Hospital, Melbourne, Victoria, Australia

John Powderly

5Carolina BioOncology Institute, Huntersville, NC, USA

Timothy Wyant

Aff81 grid.421631.30000000404088900Curis, Inc. Lexington MA USA

James Vasselli

12Aulos Bioscience, San Francisco, CA, USA

Drew Rasco

5START San Antonio, San Antonio, TX, USA

Meredith McKean

2Sarah Cannon Research Institute, Nashville, TN, USA

Elizabeth Ahern

School of Clinical Sciences, Monash University, Clayton, Victoria, Australia

Sophia Frentzas

Department of Medical Oncology, Monash Health, Melbourne, Victoria, Australia

Andrew Weickhardt

10Olivia Newton-John Cancer Wellness and Res, Heidelberg, VT, Australia

Inbar Amit

1Biolojic Design, Rehovot, Israel

Aron Knickerbocker

3Aulos Bioscience, LARKSPUR, CA, United States

Yanay Ofran

4Aulos Bioscience & Biolojic Design, Rehovot, Israel

Paul de Souza

5Western Sydney University, Campbelltown, Australia

Jenny Tang

10Aulos Bioscience, Larkspur, CA, USA

Lori Richards

10Aulos Bioscience, Larkspur, CA, USA